Short answer
Krystal Biotech, Inc. (KRYS) filed an 8-K current report with the SEC on May 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q1 2026 financial results announced for quarter ended March 31, 2026.
Krystal Biotech, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q1 2026 financial results announced for quarter ended March 31, 2026
- Full results and management commentary provided in Exhibit 99.1
- Results disclosure excluded from Exchange Act Section 18 liability and automatic registration-statement incorporation
Item EX-99.1 · Exhibit EX-99.1
- 1Q26 VYJUVEK revenue $116.4M, up 32% YoY, with 95% gross margin supporting strong commercial profitability
- Net income $55.9M, or $1.83 diluted EPS, versus $35.7M and $1.20 in 1Q25
- Cash and investments $1.0B, providing substantial funding for pipeline expansion without immediate financing pressure
- KB803 enrollment complete with 16 patients; top-line corneal abrasion data expected in 4Q26
- KB801 data expected before year-end; FDA platform designations for KB407 and KB111 could shorten follow-on development and CMC review cycles
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Krystal Biotech, Inc. 8-K filings
Get the next KRYS 8-K as it lands
Follow KRYS for push alerts, or ask the research agent what this filing means.